Cargando…
The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction
Therapies that target specific tumor drivers or immune checkpoints are increasingly explored for esophageal cancer patients. This review addresses developments in therapies with targeted anti-human epidermal growth factor receptor 2 (HER2) agents and immune checkpoint inhibitors in patients with sta...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852184/ https://www.ncbi.nlm.nih.gov/pubmed/35836094 http://dx.doi.org/10.1007/s13304-022-01327-0 |
_version_ | 1784872558261174272 |
---|---|
author | Valkema, M. J. Mostert, B. Lagarde, S. M. Wijnhoven, B. P. L. van Lanschot, J. J. B. |
author_facet | Valkema, M. J. Mostert, B. Lagarde, S. M. Wijnhoven, B. P. L. van Lanschot, J. J. B. |
author_sort | Valkema, M. J. |
collection | PubMed |
description | Therapies that target specific tumor drivers or immune checkpoints are increasingly explored for esophageal cancer patients. This review addresses developments in therapies with targeted anti-human epidermal growth factor receptor 2 (HER2) agents and immune checkpoint inhibitors in patients with stage IV esophageal cancer. First-line palliative treatment with the anti-HER2 agent trastuzumab in combination with chemotherapy has been approved for use in patients with HER2 positive gastro-esophageal adenocarcinoma. Neoadjuvant chemoradiotherapy plus perioperative trastuzumab however has not demonstrated a survival benefit in advanced esophageal cancer patients eligible for surgery. Potentially better responses are expected with dual agent anti-HER2 therapy instead of monotherapy. In the metastatic setting, the antibody–drug conjugate trastuzumab deruxtecan is effective after progression on trastuzumab. Nivolumab and pembrolizumab, antibodies blocking the programmed cell death 1 (PD-1) receptor on T cells, have recently gained approval for clinical use in esophageal cancer patients for specific indications. Synergistic effects might be achieved with combinations of immune checkpoint inhibitors that target PD-1 on T cells or PD ligand 1 (PD-L1) on tumor cells and anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) receptor on T cells. Multiple clinical trials investigating combinations of targeted and immunotherapies, with or without (neo)adjuvant chemo(radio)therapy, for curative and palliative treatment, are underway, and are expected to deliver a long-awaited improvement in the prognosis of esophageal cancer patients. |
format | Online Article Text |
id | pubmed-9852184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-98521842023-01-21 The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction Valkema, M. J. Mostert, B. Lagarde, S. M. Wijnhoven, B. P. L. van Lanschot, J. J. B. Updates Surg Review Article Therapies that target specific tumor drivers or immune checkpoints are increasingly explored for esophageal cancer patients. This review addresses developments in therapies with targeted anti-human epidermal growth factor receptor 2 (HER2) agents and immune checkpoint inhibitors in patients with stage IV esophageal cancer. First-line palliative treatment with the anti-HER2 agent trastuzumab in combination with chemotherapy has been approved for use in patients with HER2 positive gastro-esophageal adenocarcinoma. Neoadjuvant chemoradiotherapy plus perioperative trastuzumab however has not demonstrated a survival benefit in advanced esophageal cancer patients eligible for surgery. Potentially better responses are expected with dual agent anti-HER2 therapy instead of monotherapy. In the metastatic setting, the antibody–drug conjugate trastuzumab deruxtecan is effective after progression on trastuzumab. Nivolumab and pembrolizumab, antibodies blocking the programmed cell death 1 (PD-1) receptor on T cells, have recently gained approval for clinical use in esophageal cancer patients for specific indications. Synergistic effects might be achieved with combinations of immune checkpoint inhibitors that target PD-1 on T cells or PD ligand 1 (PD-L1) on tumor cells and anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) receptor on T cells. Multiple clinical trials investigating combinations of targeted and immunotherapies, with or without (neo)adjuvant chemo(radio)therapy, for curative and palliative treatment, are underway, and are expected to deliver a long-awaited improvement in the prognosis of esophageal cancer patients. Springer International Publishing 2022-07-14 2023 /pmc/articles/PMC9852184/ /pubmed/35836094 http://dx.doi.org/10.1007/s13304-022-01327-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Valkema, M. J. Mostert, B. Lagarde, S. M. Wijnhoven, B. P. L. van Lanschot, J. J. B. The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction |
title | The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction |
title_full | The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction |
title_fullStr | The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction |
title_full_unstemmed | The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction |
title_short | The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction |
title_sort | effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852184/ https://www.ncbi.nlm.nih.gov/pubmed/35836094 http://dx.doi.org/10.1007/s13304-022-01327-0 |
work_keys_str_mv | AT valkemamj theeffectivityoftargetedtherapyandimmunotherapyinpatientswithadvancedmetastaticandnonmetastaticcanceroftheesophagusandesophagogastricjunction AT mostertb theeffectivityoftargetedtherapyandimmunotherapyinpatientswithadvancedmetastaticandnonmetastaticcanceroftheesophagusandesophagogastricjunction AT lagardesm theeffectivityoftargetedtherapyandimmunotherapyinpatientswithadvancedmetastaticandnonmetastaticcanceroftheesophagusandesophagogastricjunction AT wijnhovenbpl theeffectivityoftargetedtherapyandimmunotherapyinpatientswithadvancedmetastaticandnonmetastaticcanceroftheesophagusandesophagogastricjunction AT vanlanschotjjb theeffectivityoftargetedtherapyandimmunotherapyinpatientswithadvancedmetastaticandnonmetastaticcanceroftheesophagusandesophagogastricjunction AT valkemamj effectivityoftargetedtherapyandimmunotherapyinpatientswithadvancedmetastaticandnonmetastaticcanceroftheesophagusandesophagogastricjunction AT mostertb effectivityoftargetedtherapyandimmunotherapyinpatientswithadvancedmetastaticandnonmetastaticcanceroftheesophagusandesophagogastricjunction AT lagardesm effectivityoftargetedtherapyandimmunotherapyinpatientswithadvancedmetastaticandnonmetastaticcanceroftheesophagusandesophagogastricjunction AT wijnhovenbpl effectivityoftargetedtherapyandimmunotherapyinpatientswithadvancedmetastaticandnonmetastaticcanceroftheesophagusandesophagogastricjunction AT vanlanschotjjb effectivityoftargetedtherapyandimmunotherapyinpatientswithadvancedmetastaticandnonmetastaticcanceroftheesophagusandesophagogastricjunction |